ClinicalTrials.gov
public full text
Public Domain
SGLT2 Inhibition: Uric Acid Excretion Study
The current study investigates the effects of SGLT2 inhibitor empagliflozin on uric acid excretion.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care#152581
- SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease#918411
- Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease#862735
- Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)#857349
- Supplementary Material for: Urinary Glucose Concentration as a Predictor of Proteinuria Reduction in CKD Patients Treated with SGLT2 Inhibitors#363843
Record · ID 1352165
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive